about
Androgen control of lipid metabolism in prostate cancer: novel insights and future applicationsMaximizing the Therapeutic Potential of HSP90 InhibitorsCirculating microRNAs: macro-utility as markers of prostate cancer?Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancerGSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cellsSki-interacting protein (SKIP) interacts with androgen receptor in the nucleus and modulates androgen-dependent transcription.Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells.Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.Dual roles of PARP-1 promote cancer growth and progression.Endosomal gene expression: a new indicator for prostate cancer patient prognosis?Altered endosome biogenesis in prostate cancer has biomarker potential.Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.The dynamic and static modification of the epigenome by hormones: a role in the developmental origin of hormone related cancers.Targeting cell cycle and hormone receptor pathways in cancer.Finding the place of histone deacetylase inhibitors in prostate cancer therapy.Ex vivo culture of human prostate tissue and drug development.Molecular pathology and prostate cancer therapeutics: from biology to bedside.Bringing androgens up a NOTCH in breast cancer.MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2.A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.Prostate cell lines as models for biomarker discovery: performance of current markers and the search for new biomarkers.Molecular and structural basis of androgen receptor responses to dihydrotestosterone, medroxyprogesterone acetate and Δ(4)-tibolone.Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers.An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity.High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors.Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation.Erratum to: IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptorGlobal levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion.Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein.Peri-Prostatic Adipose Tissue: The metabolic microenvironment of prostate cancer.Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.Differential effects of exogenous androgen and an androgen receptor antagonist in the peri- and postpubertal murine mammary gland.Identification of prostate cancer-associated microRNAs in circulation using a mouse model of disease.Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor explants.New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome.
P50
Q26748844-E65FB3FD-42BB-4F75-87D8-71629749300FQ26798318-9B3D87C1-7226-4899-A30B-BBC4020E9B7DQ27000024-71D4CD37-DEB0-4109-910B-7B481862F015Q28291526-38259BD2-0F6D-4B5B-B7D4-9863742A3066Q28477278-8D71A3A3-B1B1-4D63-9BAE-5E032E3FA776Q28910351-3BC7300A-81BA-4631-A933-E63D3829CBDAQ35858203-602B8B2B-3A95-4D48-B74B-BFA4C10975E8Q36130090-8D301268-1DCA-49B8-B81A-BE6E16A75839Q36460391-4F2FBC05-A831-4F91-BBF4-B4BBA33CBE5DQ36545920-C8F5CD88-896A-43FA-B062-3251788031E1Q36591621-D5E10247-04E6-41BE-8BDA-4839E2A0C3DEQ37093536-B2183A89-A4BE-4C3A-97AB-D73387C73E8CQ37376535-54305EC1-1992-4072-AB02-CF38E7D60C4CQ37502364-65D7DC2E-A20D-4727-9D6B-555FA170EC34Q37960198-32AEBAB9-E526-4B65-8F81-C02B90105CCFQ38113460-4F044107-AF08-4999-8A38-49B7425FBE3CQ38151036-C2997496-FCBA-4FC0-A6C4-F990BF7499D9Q38227009-FA6277AC-E8D5-4A31-80D3-1E193558C7C1Q38724560-80A7D90B-10BB-4692-8C0E-2F7674EE8707Q38740513-47163547-B27F-4D44-84B4-B4F31913BD63Q38766156-E7F9D399-42A0-4339-99C6-FC979D049F18Q39033586-899BC83B-2524-4EC1-AE09-558403DBD778Q39062644-723EAE19-B088-4D6F-9CF5-54D4AC25650AQ39316736-A2CBDD25-D8F7-4FE2-980F-3FE985A1A137Q39327555-258D9840-C2EC-4DC3-80C2-0EF17F5B6CC9Q39694512-AA8BAB63-00D2-40AB-A0D7-94E9D81F0E62Q42436848-14BA2089-6DB8-480F-AF64-55C802217DF2Q42439577-2BEE71DB-A6E6-4C83-A565-37FF651AE459Q42631285-13CA06D1-5F13-43C7-8CF6-C8EFD0AFB291Q43607238-0288CB38-78D9-4168-8AA8-7DC02A581B55Q48121004-E16AEFC3-BA05-4B15-B42E-FCD00F05EA66Q48288989-FDBEBA1E-982B-45F6-B68F-CC938D9FA783Q49578242-9F486334-652F-4BBB-91ED-3D8773DFB153Q49823218-4D6423A0-681E-4802-BC60-1834283F5FC3Q50953697-34258719-ED4D-4329-A783-7BB82F5BC555Q51425380-946741D3-E84D-4C81-B7FB-42B9085C068DQ51808464-7247E071-CC47-47D5-B345-CB00AAD14C33Q52327617-A6AD71B9-E031-4AF8-98D1-220290BFA1DFQ52659701-9AFC13B2-7460-4AAA-A384-828C45A7B891Q52668715-758F080E-5504-4947-B232-F9742F27A8E7
P50
description
researcher ORCID ID = 0000-0003-2698-3220
@en
wetenschapper
@nl
name
Lisa M Butler
@ast
Lisa M Butler
@en
Lisa M Butler
@es
Lisa M Butler
@nl
type
label
Lisa M Butler
@ast
Lisa M Butler
@en
Lisa M Butler
@es
Lisa M Butler
@nl
prefLabel
Lisa M Butler
@ast
Lisa M Butler
@en
Lisa M Butler
@es
Lisa M Butler
@nl
P106
P21
P31
P496
0000-0003-2698-3220